ANIP
Ani Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000
$72.00Close
$1.6BMarket cap
$70.16 – $94.4852-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- Earnings growing EPS +168% year on year, faster than the quarter before (+93 pts)
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 23 · weaker than 77% of stocks over 12 months
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
24%
1wk
down 0.8%
price change
1mo
down 0.9%
price change
12-month return
down 22%
market up 11% ·
its own down 33%
F-score
—
— Not assessed
Altman Z
2.32
Moderate risk
P/E
20.8×
price / earnings
PEG
—
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
up 6.8%
EBIT / enterprise value
Cheaper than
75%
of the market · cheap
Revenue growth
up 44%
year on year
EPS growth
up 168%
latest quarter · +93 pts
Sales growth
up 26%
latest quarter · +5 pts
ROE
up 17%
return on equity
Free cash margin
up 19%
$171.4M FCF
D/E
0.54
long-term debt / equity
Net debt / EBITDA
0.0×
Interest cover
3.4×EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 6% ($0.3B → $0.3B)
Trade setup
ATR%
2.8%
$2.02 a day · 2×ATR $67.97
RS
23 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.25
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 1 of 8
- Within 25% of the 52-week high: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 6.6% over the year, from 21m to 22m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 7, 2026
Results reaction
Aug 7, 2026-9% vs market2 sessions after results
Financials
- Net 9%
- Free cash 19%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M |
| Gross margin | 58% | — | — | — | — | — |
| Operating income | -$16.0M | -$39.8M | -$35.3M | $47.0M | $584,000 | $111.1M |
| Net income | -$22.5M | -$43.0M | -$48.0M | $19.0M | -$19.0M | $78.0M |
| Net margin | -11% | -20% | -15% | 4% | -3% | 9% |
| Earnings per share | -$1.88 | -$3.41 | -$2.95 | $1.04 | -$0.98 | $3.67 |
| Free cash flow | $9.1M | $765,000 | -$40.1M | $110.1M | $47.8M | $171.4M |
| Free cash margin | 4% | 0% | -13% | 23% | 8% | 19% |
| Cash | $7.9M | $100.3M | $48.2M | $221.1M | $144.9M | $285.6M |
| Long-term debt | $172.4M | $286.5M | $285.7M | $284.8M | $309.1M | $291.8M |
| Shareholders' equity | $195.7M | $333.9M | $313.7M | $432.7M | $403.7M | $540.7M |
| Shares outstanding | — | — | — | — | 21.11m | 22.49m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 24, 2026 | Director or officer change ↗ |
| Aug 7, 2026 | Results · Regulation FD ↗ |
| May 21, 2026 | Director or officer change · Shareholder vote ↗ |
| May 13, 2026 | Regulation FD ↗ |
| May 8, 2026 | Results ↗ |
| Apr 7, 2026 | Auditor change ↗ |
| Mar 3, 2026 | Regulation FD ↗ |
| Feb 27, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Dec 1, 2025 | Director or officer change · Regulation FD ↗ |
| Nov 10, 2025 | Results · Regulation FD ↗ |
| Nov 7, 2025 | Results ↗ |